Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Primary Sclerosing Cholangitis
NCT00953615Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Apr 2006
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in Primary Sclerosing Cholangitis (PSC), sponsored by Mayo Clinic. Primary endpoints: Alkaline Phosphatase at 6 months, Aspartate Aminotransferase at 6 months and 1 more. Started Apr 2006; status: terminated.
02
Drugs
thalidomide
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT00953615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953615.